FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029838719> ?p ?o ?g. }

• W2029838719 endingPage "408" @default.
• W2029838719 startingPage "403" @default.
• W2029838719 abstract "Prostate cancer is predominantly associated with osteoblastic bone metastases, but an increase in bone resorption has been demonstrated consistently, both histologically and biochemically. For this reason, bisphosphonates, which effectively suppress bone resorption, have been used in patients with prostate cancer metastatic to the skeleton. We studied clinical and biochemical responses 5 days and 3 months after administration of the new, potent bisphosphonate, olpadronate, in 28 patients with prostate cancer and bone metastases. All patients received 4 mg of olpadronate intravenously daily for 5 days. No additional treatment was given to the first 12 patients, while treatment was continued with oral olpadronate 200 mg daily in the following 16 patients. Serum alkaline phosphatase (ALP) activity was elevated in 93% of the patients and was positively correlated to urinary hydroxyproline excretion (r = 0.81, p < 0.0001), suggesting a coupling between bone formation and resorption. A rapid and significant suppression of bone resorption was observed in all patients after intravenous treatment. This was sustained for 4-6 weeks in all patients, but reversed thereafter in patients not receiving oral maintenance therapy. No significant changes in serum ALP activity were observed in either group during the 3 months of follow-up. At the start of treatment all patients had severe bone pain and 82% and 36% were using NSAIDs and/or opiates, respectively. Although clinical response was not a primary objective of the study, we observed that intravenous therapy was associated with a decrease in bone pain in 76% of patients and a reduction in the use of analgesics. At 3 months this response was generally sustained only in those patients who were maintained on continuous oral therapy (p < 0.05 compared with the group treated with intravenous olpadronate only). The clinical response thus appeared to parallel the biochemical changes in bone resorption." @default.
• W2029838719 created "2016-06-24" @default.
• W2029838719 creator A5016695170 @default.
• W2029838719 creator A5034308377 @default.
• W2029838719 creator A5057643841 @default.
• W2029838719 creator A5081093413 @default.
• W2029838719 creator A5091368864 @default.
• W2029838719 date "1998-04-01" @default.
• W2029838719 modified "2023-10-03" @default.
• W2029838719 title "Effects of the Bisphosphonate Olpadronate in Patients With Carcinoma of the Prostate Metastatic to the Skeleton" @default.
• W2029838719 cites W1906721103 @default.
• W2029838719 cites W1972757089 @default.
• W2029838719 cites W1974691308 @default.
• W2029838719 cites W1984749582 @default.
• W2029838719 cites W1988796857 @default.
• W2029838719 cites W1994955127 @default.
• W2029838719 cites W1996874799 @default.
• W2029838719 cites W1996898338 @default.
• W2029838719 cites W1999584604 @default.
• W2029838719 cites W2015771418 @default.
• W2029838719 cites W2022531799 @default.
• W2029838719 cites W2036488551 @default.
• W2029838719 cites W2037372719 @default.
• W2029838719 cites W2041761907 @default.
• W2029838719 cites W2044011316 @default.
• W2029838719 cites W2048744408 @default.
• W2029838719 cites W2051278879 @default.
• W2029838719 cites W2055891851 @default.
• W2029838719 cites W2060346339 @default.
• W2029838719 cites W2063068824 @default.
• W2029838719 cites W2086556166 @default.
• W2029838719 cites W2088392474 @default.
• W2029838719 cites W2097514725 @default.
• W2029838719 cites W2103009146 @default.
• W2029838719 cites W2130073993 @default.
• W2029838719 cites W2316096113 @default.
• W2029838719 cites W2403355975 @default.
• W2029838719 cites W2415481317 @default.
• W2029838719 cites W2466269338 @default.
• W2029838719 cites W26375256 @default.
• W2029838719 doi "https://doi.org/10.1016/s8756-3282(97)00289-5" @default.
• W2029838719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9556142" @default.
• W2029838719 hasPublicationYear "1998" @default.
• W2029838719 type Work @default.
• W2029838719 sameAs 2029838719 @default.
• W2029838719 citedByCount "73" @default.
• W2029838719 countsByYear W20298387192012 @default.
• W2029838719 countsByYear W20298387192013 @default.
• W2029838719 countsByYear W20298387192014 @default.
• W2029838719 countsByYear W20298387192017 @default.
• W2029838719 countsByYear W20298387192019 @default.
• W2029838719 crossrefType "journal-article" @default.
• W2029838719 hasAuthorship W2029838719A5016695170 @default.
• W2029838719 hasAuthorship W2029838719A5034308377 @default.
• W2029838719 hasAuthorship W2029838719A5057643841 @default.
• W2029838719 hasAuthorship W2029838719A5081093413 @default.
• W2029838719 hasAuthorship W2029838719A5091368864 @default.
• W2029838719 hasConcept C121608353 @default.
• W2029838719 hasConcept C126322002 @default.
• W2029838719 hasConcept C126894567 @default.
• W2029838719 hasConcept C170033053 @default.
• W2029838719 hasConcept C2776139714 @default.
• W2029838719 hasConcept C2776235491 @default.
• W2029838719 hasConcept C2776541429 @default.
• W2029838719 hasConcept C2777251235 @default.
• W2029838719 hasConcept C2777783956 @default.
• W2029838719 hasConcept C2779797417 @default.
• W2029838719 hasConcept C2780192828 @default.
• W2029838719 hasConcept C673006 @default.
• W2029838719 hasConcept C71924100 @default.
• W2029838719 hasConcept C90924648 @default.
• W2029838719 hasConceptScore W2029838719C121608353 @default.
• W2029838719 hasConceptScore W2029838719C126322002 @default.
• W2029838719 hasConceptScore W2029838719C126894567 @default.
• W2029838719 hasConceptScore W2029838719C170033053 @default.
• W2029838719 hasConceptScore W2029838719C2776139714 @default.
• W2029838719 hasConceptScore W2029838719C2776235491 @default.
• W2029838719 hasConceptScore W2029838719C2776541429 @default.
• W2029838719 hasConceptScore W2029838719C2777251235 @default.
• W2029838719 hasConceptScore W2029838719C2777783956 @default.
• W2029838719 hasConceptScore W2029838719C2779797417 @default.
• W2029838719 hasConceptScore W2029838719C2780192828 @default.
• W2029838719 hasConceptScore W2029838719C673006 @default.
• W2029838719 hasConceptScore W2029838719C71924100 @default.
• W2029838719 hasConceptScore W2029838719C90924648 @default.
• W2029838719 hasIssue "4" @default.
• W2029838719 hasLocation W20298387191 @default.
• W2029838719 hasLocation W20298387192 @default.
• W2029838719 hasOpenAccess W2029838719 @default.
• W2029838719 hasPrimaryLocation W20298387191 @default.
• W2029838719 hasRelatedWork W2013741646 @default.
• W2029838719 hasRelatedWork W2029838719 @default.
• W2029838719 hasRelatedWork W2082107301 @default.
• W2029838719 hasRelatedWork W2096275148 @default.
• W2029838719 hasRelatedWork W2122621462 @default.
• W2029838719 hasRelatedWork W2163875590 @default.
• W2029838719 hasRelatedWork W2412105987 @default.
• W2029838719 hasRelatedWork W3047667821 @default.

• next